Table 2.
Expression of CD160 and CD200 on B lymphocytes of healthy subjects and on leukemic cell clone of the patients
|
CLL (n = 30) |
MBN (n = 30) |
Control
(n = 20) |
p | ||
|---|---|---|---|---|---|
|
BNHL
(n = 25) |
HCL
(n =5) |
||||
| CD160 % | |||||
| Negative (<20) | 3 (10%) | 10 (40%) | 2 (40%) | 20 (100%) | <0.001* |
| Positive (≥20) | 27 (90%) | 15 (60%) | 3 (60%) | 0 (0%) | |
| Min. – Max. | 0.0 – 99.12 | 0.0 – 96.67 | 0.0 – 95.95 | 0.0 – 1.74 | |
| Mean ± SD. | 70.14b± 30.12 | 42.42ab ± 38 | 45.1b ± 45.6 | 0.35 ± 0.54 | |
| Median | 83.62 | 50.57 | 43.5 | 0.09 | |
| CD160 MFIR | |||||
| Negative (<2) | 1 (3.3%) | 5 (20%) | 2 (40%) | 20 (100%) | <0.001* |
| Positive (≥2) | 29 (96.7%) | 20 (80%) | 3 (60%) | 0 (0%) | |
| Min. – Max. | 0.0 – 24.16 | 0.0 – 27.8 | 0.0 – 11.4 | 0.0 – 0.75 | |
| Mean ± SD. | 10.69b± 6.28 | 8.15ab ± 7.34 | 5.21b ± 5.57 | 0.29 ± 0.28 | |
| Median | 8.60 | 5.68 | 3.94 | 0.26 | |
| CD200 % | |||||
| Negative (<20) | 0 (0%) | 11 (44%) | 0 (0%) | 20 (100%) | <0.001* |
| Positive (≥20) | 30 (100%) | 14 (56%) | 5 (100%) | 0 (0%) | |
| Min. – Max. | 64.64 - 99.82 | 0.0 – 99.50 | 52.13 – 95.2 | 2.98 – 18.0 | |
| Mean ± SD. | 96.44b±6.44 | 44.8ab± 43.5 | 82.9b ± 17.6 | 10.2± 4.62 | |
| Median | 98.45 | 33.4 | 90.08 | 4.61 | |
| CD200 MFIR | |||||
| Negative (<20) | 15 (50%) | 19 (76%) | 2 (40%) | 20 (100%) | <0.001* |
| Positive (≥20) | 15 (50%) | 6 (24%) | 3 (60%) | 0 (0%) | |
| Min. – Max. | 7.45 - 44.52 | 0.0 – 66.6 | 11.8 – 36.02 | 6.28- 11.06 | |
| Mean ± SD. | 20.85b±8.46 | 12.6ab ± 14.4 | 20.3b ± 9.77 | 8.40 ± 1.56 | |
| Median | 19.67 | 8.75 | 20.3 | 8.18 | |
| CD160+ve%,CD160MFIR+ve | 27 b (90.0%) | 15ab (60.0%) | 3b (60.0%) | 0(0.0%) | <0.001* |
| CD160+ve%, CD160MFIR-ve | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | – |
| CD160-ve%, CD160MFIR+ve | 2(6.7%) | 5(20.0%) | 0(0.0%) | 0(0.0%) | 0.131 |
| CD160-ve%, CD160MFIR-ve | 1 b (3.3%) | 5 b (20.0%) | 2ab(40.0%) | 20(100.0%) | <0.001* |
| CD200+ve%, CD200MFIR+ve | 15b(50.0%) | 1a(4.0%) | 3b(60.0%) | 0(0.0%) | <0.001* |
| CD200+ve%, CD200MFIR-ve | 15b(50.0%) | 13b(52.0%) | 2b(40.0%) | 0 (0%) | <0.001* |
| CD200-ve%, CD200MFIR+ve | 0(0.0%) | 5a(20.0%) | 0(0.0%) | 0(0.0%) | 0.011* |
| CD200-ve%, CD200MFIR-ve | 0b(0.0%) | 6ab(24.0%) | 0b(0.0%) | 20(100.0%) | <0.001* |
a: Significant with CLL
b: Significant with Control
Quantitative data was expressed in mean ± SD, median (Min. - Max.) and compared usingF ANOVA test or Kruskal Wallis test. Qualitative data were described using number and percentage and was compared using Chi square or Monte Carlo test
*
: Statistically significant at p ≤ 0.05 MFIR: mean fluorescence intensity ratio;CLL:chronic lymphocytic leukemia ; MBN: mature B-cell neoplasms ;B-NHL :B-non hodgkin lymphoma ; HCL: hairy cell leukemia